Anti-EGFR/Anti-c-Met Monoclonal Antibody FPI-2053

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A humanized bispecific monoclonal antibody targeting epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (HGFR; c-Met), that can potentially be used as a ligand in radiotherapy. Upon administration, anti-EGFR/anti-c-Met monoclonal antibody FPI-2053 simultaneously targets and binds to the extracellular domains of both EGFR and c-Met expressed on cancer cells. EGFR and c-Met, both upregulated or mutated in a variety of tumor cell types, play key roles in tumor cell proliferation.

**Synonyms:** - Anti-EGFR x Anti-c-Met Monoclonal Antibody FPI-2053 - Anti-EGFR/Anti-c-Met Bispecific Antibody FPI-2053 - Anti-EGFR/c-Met Antibody FPI-2053 - FPI 2053 - FPI-2053 - FPI2053